Liquidia Technologies has presented preclinical and Phase 1 study results for its LIQ861 inhaled treprostinil for the treatment of pulmonary arterial hypertension at the Annual World Congress of the Pulmonary Vascular Research Institute (PVRI), noting that the data supported advancement of LIQ861 into the INSPIRE Phase 3 trial which was initiated earlier this month. … [Read more...] about Liquidia announces positive results from Phase 1 trial of LIQ861 trepostinil DPI
News
Hovione adds DPI capsule filling capacity
Hovione has announced the addition of a new MG2 Tekna capsule filler for filling DPI capsules at the company's Loures, Portugal facilities. The MG2 Tekna machine, which has a capacity of up to 110,000 capsules/hour with 100% fill weight check, can be used for filling highly potent compounds. The company said in the announcement, "This investment reinforces … [Read more...] about Hovione adds DPI capsule filling capacity
Iceland approves Penthrox inhaled methoxyflurane
The Icelandic Medicines Agency has approved an MAA filed by Medical Developments International (MVP) to allow marketing of Penthrox inhaled methoxyflurane for the treatment of pain due to traumatic injury. The company said that Penthrox would be available for sale in Iceland immediately after the approval, which was dated January 16, 2018. In December 2017, MVP … [Read more...] about Iceland approves Penthrox inhaled methoxyflurane
Pulmatrix announces Phase 1/1b study of Pulmazole inhaled intraconazole
The UK Medicines and Healthcare Products Regulatory Agency has approved a Clinical Trial Application filed by Pulmatrix for a Phase 1/1b study of Pulmazole (PUR1900) inhaled dry powder itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients, the company said. In October 2017, Pulmatrix announced that PUR1900 received … [Read more...] about Pulmatrix announces Phase 1/1b study of Pulmazole inhaled intraconazole
Adherium opens new corporate headquarters in US
Smartinhaler maker Adherium has opened a new corporate headquarters in San Mateo, California, the company said. In 2017, the company announced that it had sold more than 100,000 Smartinhaler inhaler monitoring systems. Adherium CEO Arik Anderson commented, “Our headquarters at 1800 Gateway Drive deepens our existing footprint in Silicon Valley, as we take the … [Read more...] about Adherium opens new corporate headquarters in US
Copley Scientific launches new Breath Actuation Controller for MDI testing
Copley Scientific has announced the launch of the BAC 2100 Breath Actuation Controller for automated flow control during cascade impaction and delivered dose uniformity testing of metered dose inhalers. The company is also launching the BAC 2100-R, with reversed flow inlet and outlets. The new versions of the BAC include automated cascade impactor leak testing, an … [Read more...] about Copley Scientific launches new Breath Actuation Controller for MDI testing
Roger Jeffs joins board of Spyryx Biosciences
Spyryx Biosciences, which recently initiated a Phase 2 study of its SPX-101 inhaled SPLUNC1-derived peptide for the treatment of cystic fibrosis, announced that former United Therapeutics CEO Roger Jeffs has joined its board of directors. Jeffs served as President and COO of United Therapeutics from 1998-2014 and as President and CEO from January 2015 until mid … [Read more...] about Roger Jeffs joins board of Spyryx Biosciences
3P Innovation to build new UK facility
3P innovation, which recently launched a new robotic filling machine capable of filling inhalers as well as capsules, says that it has started work on a new facility at Tournament Fields near Warwick, UK. The 30,000 sq ft facility, which is expected to be complete in the 4th quarter of 2018, will have room for expanded operations, including early development lab … [Read more...] about 3P Innovation to build new UK facility
FDA advisory committee votes against approval of Linhaliq
Aradigm Corporation said that the FDA's Antimicrobial Drugs Advisory Committee (ADAC) has voted against approval of the company's NDA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in non-cystic fibrosis bronchiectasis (NCFBE) patients. The company submitted the NDA in July 2017, and the FDA granted the … [Read more...] about FDA advisory committee votes against approval of Linhaliq
Eurocine Vaccines announces Phase 1/2 study of Immunose Flu vaccine
Eurocine Vaccines has received authorization from the Swedish Medical Products Agency for a Phase 1/2 clinical study of its intranasal quadrivalent influenza vaccine Immunose Flu during the current flu season, the company said. Eurocine Vaccines also ran a Phase 1/2 study of Immunose Flu in 2016. Immunose Flu is based on the company's Endocine nasal vaccine … [Read more...] about Eurocine Vaccines announces Phase 1/2 study of Immunose Flu vaccine